APP and Alzheimer disease: Controversially, selective somatostatin/NPY inhibitory interneurons neurodegeneration has been described in the hippocampus of a transgenic presenilin 1 PS1/APP AD model, with preservation of GABAergic mRNA synaptic markers (Ramos et al., 2006).